Diag Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Diag Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$2.15M	Buy	+139,531	New	+$2.86M	2.46%	19

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Diag Capital Management's TEVA Position: Q4 2018 in Review

Diag Capital Management opened a new position in Teva Pharmaceuticals (TEVA) in Q4 2018: 139,531 shares worth $2.15M. The stake represents 2.46% of the portfolio and ranks #19 among its holdings.

552 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

Diag Capital Management held 139,531 shares of Teva Pharmaceuticals worth $2.15M as of Q4 2018.
Teva Pharmaceuticals was a new Diag Capital Management position in Q4 2018.
Teva Pharmaceuticals made up 2.46% of Diag Capital Management's portfolio in Q4 2018, its #19 holding.
552 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Diag Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.